The Top Line AbbVie, ADCs and the future of cancer care
Jun 20, 2025
Daejin Abidoye, M.D., is the Vice President and therapeutic area head for solid tumor oncology at AbbVie. In this engaging conversation, he delves into the transformative potential of antibody-drug conjugates (ADCs) in cancer care. He discusses AbbVie's breakthrough approval of Emrelis for lung cancer, the promising future of ADCs beyond chemotherapy, and exciting advancements from the recent ASCO conference. Abidoye also highlights innovative compounds targeting various cancers and the growing importance of precision medicine in oncology.
AI Snips
Chapters
Transcript
Episode notes
AbbVie's Oncology Evolution
- AbbVie's shift to solid tumors is an evolution, not a complete change, building on its hematology success.
- Their ADC platform targets high unmet needs like CMET in non-small cell lung cancer, showing promising clinical outcomes.
TMAPA ADC Shows Broad Activity
- Next-generation CMET targeting ADC TMAPA shows strong response rates in heavily pretreated non-small cell lung cancer and colorectal cancer.
- Activity is impressive regardless of CMET expression, signaling a broad application potential.
Advancing ADCs with Robust Pipeline
- AbbVie enhances ADCs by improving antibodies, linkers, and payloads for better potency and stability.
- Multiple ADCs across ovarian, colorectal, and lung cancers show promising safety profiles that enable combination therapies.